Objectives-This study assessed the efficacy and safety of transvaginal ultrasound (US)-guided core needle biopsy (CNB) for obtaining adequate pelvic mass samples for histologic analysis and evaluated factors that may affect biopsy success.
M
any patients with primarily inoperable pelvic tumors, advanced tumors with a compromised performance status, or recurrent pelvic tumors are unlikely to achieve optimal debulking, and surgical cytoreduction does not improve their survival. In other patients with pelvic masses, timely initiation of adequate treatment requires accurate histologic verification of pelvic diseases. 1, 2 Ultrasound (US)-guided needle biopsy provides a less-invasive way to obtain tissue samples for diagnosis, avoiding the much greater invasiveness of laparoscopic biopsy and surgical biopsy. [3] [4] [5] Indeed, US-guided needle biopsy is generally accepted as effective and safe, with high accuracy for diagnosis in many clinical settings.
Fine-needle aspiration biopsy (FNAB) has been used for verification of the lesion nature since 1921 and has proved to be one of the most valuable tools for the diagnosis of tumors of the female pelvis. [6] [7] [8] Due to its simplicity and safety, FNAB is frequently used as an alternative to surgical procedures, 9 ,10 but a major limitation is the small amount of the collected sample. To address this limitation, core needle biopsy (CNB) was developed and has gained substantial popularity in recent years. Compared to FNAB, CNB provides a superior sample for histologic examination of the lesion, especially for immunohistochemical evaluation. [11] [12] [13] [14] Previous studies have shown that US-guided CNB has a higher success rate for obtaining adequate specimens than FNAB. 12 Transabdominal biopsy carries the risk of puncturing the bowel, and it may be difficult to reach a deep pelvic mass. Thus, the transvaginal approach is often the optimal route to pelvic tumors and in fact may be the only safe access in certain cases. [15] [16] [17] Moreover, recent work has demonstrated additional advantages of transvaginal US over transabdominal US. For instance, a moreadequate biopsy rate was obtained via the transvaginal route compared to the transabdominal route using USguided Tru-Cut biopsy. 18 Otherwise, most pelvic masses are close to the vagina, and vascularization can often be identified by color Doppler flow imaging, which can avoid passing great vessel to minimize bleeding risk. 3 In addition, transvaginal biopsy can minimize the rate of puncturing a tethered bowel in most women. Therefore, transvaginal US plays an increasingly important role in pelvic lesion diagnosis, although the risk of introducing infection may increase, as the sterile preparation can be insufficient when using the transvaginal route. 17 The purposes of this study were to review our experience with transvaginal US-guided CNB of pelvic masses, assess the adequacy, success rate, and safety of this diagnostic method, and evaluate factors that may affect successful recovery of an adequate biopsy sample. Our investigation of a large number of patients over 7 years could strongly expound transvaginal US-guided CNB of adnexal masses as a useful diagnostic alternative, and we present the procedures in detail to minimize its complications.
Materials and Methods
From February 2009 through January 2016, 199 consecutive female patients with diagnoses of abdominopelvic or pelvic masses from the gynecologic oncology department in our cancer center were enrolled in this study. The transvaginal US-guided CNB technique was used for tissue sampling and tumor verification before treatment planning. There were 200 cases with the potential for transvaginal CNBs and 200 CNBs (1 patient underwent 2 biopsies) were performed. The clinical data were retrospectively reviewed. The inclusion criteria were as follows: (1) advanced abdominal and pelvic tumors that would not benefit from primary oncogynecologic surgery, or the origin of the tumor was unclear, and further management required histologic verification; (2) the mass was easily visible under transvaginal US; and (3) the mass was firm in consistency either in its entirety or in a vaginally accessible area. In all patients, tumor accessibility and the feasibility of transvaginal CNB were assessed first by comparing transvaginal to transabdominal US. All patients referred for the procedure had imaging results that showed a lesion or a mass in close proximity to the vagina. Patients with coagulation dysfunction and unsatisfactory hemograms were deemed unsuitable for CNB and excluded.
The following indication groups were identified: group A (n 5 97), inoperable tumors (cases with abdominal and pelvic tumors with parameters of primary suboptimal operability); group B (n 5 13), suspicion of metastases to the ovaries or peritoneum (cases with a history of a nongynecologic tumor and current signs of secondary ovarian or peritoneal tumors); group C (n 5 45), recurrence (cases with a history of a gynecologic tumor and current uncertain signs of recurrence); and group D (n 5 45), other solid lesions (genital or nongenital rare tumors with Tru-Cut indications).
The accessibility and feasibility of CNB of the masses by the transvaginal approach were assessed first by transvaginal or transabdominal US. During the procedure, the transvaginal transducer was oriented to match the image presentation and make the target mass close to the vagina, and the interposed structures such as the bowel and bladder were manually displaced for safe access. Color Doppler flow imaging was used to assess blood flow in the mass and identify adjacent vessels. Color Doppler flow imaging settings were set to achieve maximum sensitivity and detect low-velocity flow without noise. Blood flow signals detected in the mass by color Doppler flow imaging were considered signs of vascularization; no blood flow signals in the mass were considered no vascularization.
Before the biopsy procedure, clinical indicators were measured to evaluate the patient status and prevent severe complications. The indicators routinely checked were platelet count, prothrombin time, international normalized ratio, and activated partial thromboplastin time. Generally accepted reference ranges for these coagulation parameters are summarized in Table 1 . The patients were informed before the procedure that there might be damage to structures in the path of the needle (bowel, vessels, and other organs), and written informed consent was obtained from each patient before the procedure. The study was approved by the Sun Yat-sen University Cancer Center Ethics Committee.
Biopsies were performed by experienced operators (X.-Q.P., W.Z., and X.L.) using US machines equipped with transvaginal transducers: Mylab Twice (Esaote SpA, Genoa, Italy), iU22 (Philips Healthcare, Eindhoven, the Netherlands), and LOGIQ 9 (GE Healthcare, Amersham, England). The morphologic characteristics of the tumors were recorded, and the optimum plane closest to the vagina for reaching the lesion was determined during a grayscale evaluation. Blood flow signals detected by color Doppler flow imaging were considered positive for vascularization to identify the viable parts of the tumor. Because of the anatomic features of the vagina, it was difficult to make sure that the biopsy needle passage was consistent with anesthesia needle passage, and topical spray had a weak effect on pain relief because the transvaginal biopsy should penetrate the vaginal wall; thus, with reference to previous studies, no anesthesia was used during our transvaginal CNBs. 3, 5, 18, 19 The transvaginal biopsy procedure was performed in the lithotomy position with a reusable core biopsy instrument (Bard Peripheral Vascular, Tempe AZ), which was compatible with an 18-gauge, 250-mm-long Bard TruGuide coaxial biopsy needle (MN1825). The needle was directed to the lesion with the assistance of a special needle guide attached to a transvaginal US transducer. The penetration depth was 15 or 22 mm. Core needle biopsy specimens were taken from masses in the pelvic cavity, vaginal cuff or vaginal wall, and peritoneal cake. After completion of the biopsy, the cannula was slid back. Each sample was checked for the presence and sufficiency of tissue. According to previous studies, 1 to 3 tissue cylinders 10 to 20 mm long were obtained from each patient. 18, 19 Two or 3 tissue cylinders, each 5 to 20 mm long and 1.5 mm wide (depending on the size of the biopsied lesion), were routinely obtained from each patient for histologic analysis in our study. Only if the patient was in poor physical condition was a single core was obtained. When the sample contained small fragmented tissue, a total of 3 biopsies would be performed. The tissues obtained were placed in formalin immediately. Sections from formalinfixed, paraffin-embedded tissue blocks were stained with hematoxylin-eosin. All samples were examined and classified for the presence of tumor tissue as well as suitability for immunohistochemical staining.
After the biopsy procedure, the transvaginal transducer was left in place for 5 minutes with pressure to stop bleeding, and then a sterile swab was placed at the biopsy site for another 5 minutes for hematoma. Bleeding from the biopsy site and vaginal bleeding were then checked. During the procedure, we kept aseptic conditions and had good communication with the patients to dispel tension. Patients were not hospitalized at the time of the procedure and were observed for at least 30 minutes in a dedicated recovery area with frequent vital sign monitoring before discharge. We did not obtain routine postprocedure hematocrit/hemoglobin levels if the patient was asymptomatic. We recorded evidence of needle tract seeding by a gynecologic examination during follow-up. The specimens were divided into 2 groups: adequate and inadequate. In turn, adequate specimens were subclassified as successful or inappropriate. Successful specimens were those verifying the presence of malignant or benign cells from the target organ, which were confirmed by the histological results from surgery or by clinical diagnosis. The clinical diagnosis was based on serum markers, a good response to subsequent radiotherapy or chemotherapy, or 2 years of follow-up. The tumor response to treatment was based on the change in size in light of the Response Evaluation Criteria in Solid Tumors guidelines (version 1.1). Complete and partial responses indicated a good response to treatment. 20 Inappropriate specimens were those consisting of an adequate sample size for analysis but containing a discrepant cell type for characterization of the target lesion, as subsequently verified by laparotomy or 
Results
The 199 patients included in the study ranged in age from 35 to 78 years (mean 6 SD, 52.3 6 11.6 years). A total of 200 transvaginal US-guided CNBs meeting inclusion criteria were performed during the 7-year study period. No patient was excluded because of the stated abnormal coagulation parameters. Table 2 enumerates all cases with respect to indication group and pathologic diagnosis. The specimens were obtained from pelvic cavity masses in 134 of 200 cases (67.0%) (Figure 1 ), including pelvic lymph nodes, the vaginal cuff, or the vaginal wall in 35 cases (17.5%; Figure 2 ) and the peritoneal cake in 31 cases (15.5%; Figure 3 ). One sample was taken in 31 cases; 2 samples were taken in 144 cases; and 3 samples were taken in 25 cases, with an average of 1.97 samples per case. The time required to obtain 2 tissue samples ranged from 10 to 15 minutes. All of the patients could tolerate the procedure well. No complications (eg, intolerable pain and vasovagal reactions) were observed during the biopsy procedures. All of these patients were clinically stable after the procedure, and no patient need referral to gynecology for other therapy. No feedback on complications was collected after the procedure. There was no case with bleeding, hematoma, or infection in our study. We recorded no evidence of needle tract seeding over a mean follow-up period of 13.5 months (range, 3 months-2 years).
In our study, 96 cases (48.0%) had lesion pathologic types verified by laparotomy or laparoscopy, and 104 cases were verified by clinical diagnosis. The specimens were divided into 2 groups: adequate and inadequate. Of the 200 biopsies, 192 specimens were considered adequate for histologic evaluation by hematoxylin-eosin (96.0%), and 8 biopsies were considered inadequate for complete histologic diagnosis (4.0%). The 192 adequate specimens consisted of 178 positive specimens, 12 benign specimens, and 2 inappropriate specimens in which the histologic diagnosis was not consistent with the final histologic type. Thus, 190 of 200 biopsies were considered successful (95.0%). Among the adequate specimens, 61 were also assessed by immunohistochemistry. The patients with positive specimens underwent cytoreduction surgery, primary surgery, or effective neoadjuvant chemotherapy. Among the 8 inadequate biopsies, 6 patients underwent biopsy by laparotomy for histologic diagnosis; 1 patient underwent CNB again to obtain an adequate tissue sample in agreement with the final histologic diagnosis; and 1 patient did not obtain a precise diagnosis by a repeated biopsy in another hospital. The mean length of lesion along the guide needle was 4.80 6 2.16 cm. Forty-six lesions were less 2 cm or smaller in diameter, and 154 were larger than 2 cm. The probability of obtaining a sufficient specimen was significantly higher in patients with tumors larger than 2 cm (P 5 .023). The probability of obtaining a sufficient specimen did not differ between lesions with and without vascularization (P 5 .868) and was not affected by ascites (P 5 .634), or tumor type (P 5 .813). In contrast, the biopsy site did have a significant influence on the probability of obtaining an adequate specimen for histologic verification (P < .01). Results from the univariate analysis are summarized in Table 3 .
Our study showed a significant difference (P < .05) in adequacy rates between the peritoneal cake and pelvic masses (83.9% versus 98.5%) and between the peritoneal cake and vaginal cuff masses (83.9% versus 97.1%), but not between pelvic and vaginal cuff masses (P > .99). Thus, CNBs taken from the peritoneal cake were significantly less successful than those from other biopsy sites.
Discussion
This retrospective study conducted from February 2009 to January 2016 evaluated the efficacy and safety of USguided transvaginal CNB. Core needle biopsy obtained tissue samples adequate for histologic analysis in 96.0% cases and successful diagnosis in 95.0% of cases with no complications. A peritoneal cake lesion site and size smaller than 2 cm were negative predictors of adequate sampling. In contrast, the presence of ascites, age, and tumor type were not significantly correlated with acquisition of an adequate specimen. Thus, CNB via the transvaginal approach can be used successfully for most pelvic lesions.
It is sometimes difficult to distinguish malignant from benign disease in patients with adnexal masses using medical imaging modalities. 21 Indeed, imageguided biopsy provides a less-invasive diagnostic method compared to laparoscopic and surgical biopsy. Computed tomography, magnetic resonance imaging, and US are commonly used to guide biopsy sampling of primary and recurrent pelvic masses. Each modality has its unique advantages and limitations. Computed tomography can provide excellent visualization of structural anatomy but involves radiation exposure and is not applicable for real-time visualization. [22] [23] [24] Magnetic resonance imaging is rarely used because of the prohibitive cost of prolonged imaging. Conversely, US provides real-time visualization of the target region and more flexible control of the biopsy needle and its tip than other image modalities. It is also less expensive, and examinations can be performed without radiation. 4, 25 Our study shows that tissue samples sufficient for histologic evaluation from pelvic masses can be obtained in most cases by transvaginal CNB. Real-time US guidance of the biopsy needle directly into the solid portion of the mass and lymph node is one of the central reasons for achievement of this high adequacy rate.
The choice between transvaginal and transabdominal US imaging depends on individual patient factors and lesion characteristics (size and location/accessibility). 18 A higher adequacy rate via the vaginal approach was found in 131 transvaginal Tru-Cut biopsies (94.7%) versus 64 transabdominal Tru-Cut biopsies (92.2%) under US guidance in patients with abdominal and pelvic tumors. 18 Consistent with these studies, we advocate the vaginal approach for biopsies of pelvic lesions because it is less invasive than abdominal access. Most pelvic masses are close to the vagina, and vascularization can often be identified by color Doppler flow imaging, minimizing bleeding risk. Transvaginal biopsy can minimize the rate of puncturing a tethered bowel in most women.
Biopsy of uncertain lesions can be accomplished by using either FNAB or CNB. Fine-needle aspiration biopsy has been used as the standard method for verification of primary and recurrent tumors for many years because it is minimally invasive, simple, and effective. However, samples from FNAB may be insufficient for histologic diagnosis because of their small size and occasionally confusing cytoarchitecture, which can lead to false-negative results. In addition, FNAB does not permit immunohistochemical staining, which plays a crucial role in the differential diagnosis of tumors. Several studies have compared FNAB with CNB. In a large series of 1300 computed tomographically guided biopsies from chest, abdominal, retroperitoneal, and head/neck regions, adequacy rates reached 93% to 100% with the use of an automated 16-or 18-gauge cutting-needle biopsy, with specific diagnosis rates of 82% to 100%, compared to 72% to 92% adequacy rates and 54% to 67% specific diagnosis rates for 22-gauge FNAB. 22 Kong et al 26 evaluated transvaginal US-guided core biopsy of adnexal masses for neoadjuvant chemotherapy in patients with advanced ovarian malignancies; their findings in the samples were nondiagnostic in 4 patients (5.8%), and the diagnostic accuracy was 93.6%. Consistent with these results, our study clearly demonstrates that transvaginal CNB obtains samples that are adequate for successful histologic diagnosis in most cases (96.0% adequacy and 95.0% success). We attribute the high adequacy and success to the proximity of the pelvic lesions to the transducer and real-time visualization of the tumors. Although a larger cutting needle is required for CNB than FNAB, suggesting a greater risk of bleeding, the complication rate of CNB in our study was less than that for FNAB (0.5%-1.0%) in another study. 27 There may be also a risk of tumor seeding after CNB. The potential impact of tumor seeding on the patient's future disease management should be considered. According to previous similar investigations, [15] [16] [17] no tumor seeding after CNB was found in our study. The likelihood of needle tract seeding in a case may be related to the anatomic locations and tumor type. 28 Our univariate analysis showed a higher probability of obtaining an inadequate specimen from smaller lesions, as also demonstrated previously. 18 However, even small masses can be successfully biopsied depending on their location and US visibility. In our study, the adequacy reached 89.1% (41 of 46) for masses of 2.0 cm or smaller versus 98.1% (151 for 154) for larger masses (>2.0 cm). A previous study also mentioned that the number of samples was greater for smaller lesions, 29 and it is obvious that larger tumors are easier to access. Therefore, we suggest that smaller lesions (those < 2 cm) should be sampled multiple times to obtain adequate specimens.
Our study also showed that the biopsy site had a significant effect on the biopsy adequacy rate. Of the 31 biopsies located in the peritoneal cake, 5 were insufficient for pathologic diagnosis with an 18-gauge core needle even after 2 or 3 passes. We suggest that the peritoneal cake as a biopsy site is correlated negatively with adequacy because of tissue fragility and inflammation, which is a component of the microenvironment in the tumor tissue. Therefore, it is more difficult to collect appropriate biopsies from the peritoneal cake than other biopsy sites. There have been several reports referring to US-guided CNB in the peritoneal cake. Que et al 30 achieved sensitivity of 95.6%, specificity of 92.9%, and accuracy of 93.8% using a 14-gauge spinal needle and 4 average passes to collect specimens. We share their opinion that peritoneal biopsies do have their own advantages. They are safe because the peritoneum is superficial, and patients often have ascites, which lift the region free of the underlying bowel, thereby preventing puncture of vital organs. In light of our study and that previous study, more passes should be performed and a larger needle used to ensure adequate sample size from the omental cake when the sample contains small fragmented tissue.
The lack of influence of vascularization, ascites, and tumor type in our study is in concordance with a previous study. 18 Only 2 cases were inconsistent with the final histologic diagnosis. In the first case, the histologic result from the biopsy showed poorly differentiated adenocarcinoma, whereas the final diagnosis after surgery turned out to be mesothelioma. Mesothelioma can be categorized histologically as the epithelioid type, sarcomatoid type, biphasic type, or desmoplastic type, among others. In the epithelioid and biphasic types, the poorly differentiated adenocarcinoma-like region may be easily confused under the standard histologic analysis on a microscope. 31 Immunohistochemistry and molecular diagnosis are useful for making an accurate diagnosis after surgery. 27 On the other hand, there was only 1 case with mesothelioma in our study, which may have been due to a bias attributable to the fact that the enrolled transvaginal US-guided CNBs were from the gynecologic oncology department in our cancer center. In the other case, inflammatory disease was reported based on the histologic diagnosis, whereas the final diagnosis was serous ovarian cancer. It is possible that inflammatory conditions caused by tumor cell dissemination obscured pathologic verification.
A previous study in which 5 patients underwent transvaginal Tru-Cut biopsy reported that a mass in close proximity to the bladder was a contraindication for the Tru-Cut biopsy via the vaginal approach. 15 In our study, there were no complications during the CNBs, and although no feedback on complications was collected after the procedures, we consider transvaginal USguided CNB is a very safe procedure if performed correctly, which is consistent with previous results. 32 We do think, however, that procedural safety should be emphasized. Since postbiopsy hemorrhage is the most probable complication, the approach used depends on the patient's clinical indications from routine assessment of the platelet count, prothrombin time, international normalized ratio, and activated partial thromboplastin time. In addition to patient preparation, postbiopsy observation is critical to ensure a low complication rate.
The first limitation of this study was that we did not use any anesthesia. Some woman may be apprehensive when undergoing transvaginal biopsy without anesthesia, so the use of moderate sedation or anesthesia has been suggested. 5, 33 However, in previous studies, 3, 5, 18, 19 the transvaginal approach with no anesthesia and intravenous sedation was performed for patients from the United Kingdom and Czech Republic. Westenberg et al 34 studied the pain experiences of 100 patients who underwent transrectal US-guided prostatic biopsy without anesthesia. They found that 97% of patients thought the procedure was only slightly, or not at all, uncomfortable. Second, because this work was a retrospective study, we recorded evidence of needle tract seeding by gynecologic examinations during the follow-up in our patients, which cannot be adequately assessed in that manner; furthermore, tumor seeding in the vagina may be difficult to assess. On the other hand, a lack of adequate follow-up in this group after CNB was a limitation of our study for detecting hematomas.
In conclusion, we investigated a large number (200 cases) of patients who underwent transvaginal US-guided CNB of pelvic masses. Our study shows transvaginal US guidance permits extremely accurate biopsy of pelvic lesions, especially deep pelvic tumors. Moreover, the risk of tumor seeding is minimal, and no anesthesia is needed, thus avoiding the risk of a drug allergy. We strongly recommend transvaginal US-guided CNB of adnexal masses as a useful diagnostic alternative to a cytologic examination or laparoscopy in patients with advanced ovarian cancer or suspected recurrence, since further therapy requires an accurate histologic diagnosis.
